Neuroinitiative careers

First in class disease-modifying therapeutic molecules for Parkinson's disease. We aim to get these molecules to IND and out-license to pharma for human testing in 4 years. Average licensing options for similar compounds is $400mm (upfront and milestone based).

IP of company also includes patent-pending drug discovery simulation software, which we are not planning to out-license or sell at this point in time.